Abstract: Objective To investigate the relationship between the expression levels of serum monoacylglycerol esterase (MAGL),glycerol 3 phosphate dehydrogenase 1 (GPD1),human pre circulating gastrin (hPG80) and molecular typing and prognosis in breast cancer patients.Methods A total of 121 breast cancer patients from May 2019 to May 2021 were included as the cancer group.The molecular typing was Luminal A (62 cases),Luminal B (31 cases),HER2 positive (19 cases) and triple negative (9 cases) breast cancer.According to the prognosis,there were 82 cases in the good prognosis group and 39 cases in the poor prognosis group.121 patients with benign breast lesions were selected as the benign lesion group,and another 121 healthy volunteers who underwent physical examination were included as the control group.Enzyme linked immunosorbent assay (ELISA) was applied to detect the expression levels of MAGL,GPD1,and hPG80 in all personnel serum samples.Multivariate Logistic analysis was applied to analyze the adverse prognostic factors of breast cancer patients.ROC curve was drawn to analyze the predictive value of serum MAGL,GPD1,hPG80 levels for poor prognosis of breast cancer patients.Results Compared with the control group [MAGL=(10.74±2.35)μg/L,GPD1=(6.31±1.32)μg/L,hPG80=(2.41±0.56)pmol/L],the expression level of serum hPG80 in patients of the cancer group [MAGL=(5.93±1.12)μg/L,GPD1=(4.07±0.81)μg/L,hPG80=(5.34±1.25)pmol/L] and the benign lesion group [MAGL=（7.36±1.42）μg/L，GPD1=（4.89±0.99）μg/L，hPG80=（4.75±0.82）pmol/L] increased,while the expression levels of MAGL and GPD1 decreased. The serum hPG80 in the cancer group was higher than that in the benign lesion group, while MAGL and GPD1 were lower than those in the benign lesion group, and the differences were statistically significant (P < 0.05).Serum MAGL in different molecular subtypes of breast cancer patients [Luminal A=(6.34±1.15)μg/L,Luminal B=(5.11±1.02)μg/L,HER2 positive=(7.48±1.52)μg/L,Triple negative breast cancer=(2.62±0.72)μg/L],GPD1[Luminal A=(4.15±0.83)μg/L,Luminal B=(3.87±0.79)μg/L,HER2 positive=(5.05±1.07)μg/L,Triple negative breast cancer=(2.14±0.48)μg/L],hPG80[Luminal A=(5.03±1.10)pmol/L,Luminal B=(5.86±1.40)pmol/L,HER2 positive=(4.65±1.32)pmol/L,Triple negative breast cancer=(7.13±1.35)pmol/L] showed different expression levels.The expression levels of serum MAGL and GPD1 in triple negative breast cancer patients were the lowest,and the expression level of hPG80 was the highest(P<0.05).With the increase of TNM stage,the serum levels of MAGL[Ⅰ-Ⅱ stage=(6.36±1.29)μg/L,Ⅲ-Ⅳ stage=(5.64±1.06)μg/L] and GPD1[Ⅰ-Ⅱ stage=(4.34±0.86)μg/L,Ⅲ-Ⅳ stage =(3.76±0.74)μg/L] in the cancer group gradually decreased,and the level of hPG80[Ⅰ-Ⅱ stage=(4.99±0.98)pmol/L,Ⅲ-Ⅳ stage =(5.57±1.39)pmol/L] gradually increased(P<0.05).Compared with the good prognosis group[MAGL=（6.52±1.23）μg/L，GPD1=（4.42±0.83）μg/L，hPG80=（4.96±1.05）pmol/L],the expression level of serum hPG80 in the poor prognosis[MAGL=（4.69±0.89）μg/L，GPD1=（3.34±0.67）μg/L，hPG80=（6.16±1.14）pmol/L] group was higher,and the expression levels of MAGL and GPD1 were lower(P<0.05).Multivariate Logistic analysis showed that hPG80 was a risk factor for poor prognosis of breast cancer patients,MAGL and GPD1 were protective factors(P<0.05).ROC curve revealed that the area under the curve (AUC) value of serum MAGL,GPD1 and hPG80 levels for predicting poor prognosis of breast cancer patients was 0.911,obviously higher than that of MAGL,GPD1 and hPG80 alone.Conclusion The expression level of serum hPG80 in breast cancer patients increases,while the expression level of MAGL and GPD1 decrease.The three levels are related to the molecular typing and prognosis of breast cancer patients.

Key words: breast cancer; molecular typing; monoacylglycerol esterase; glycerol 3 phosphate dehydrogenase 1; human pre circulating gastrin; prognosis